‘Unexpected demand’ hits Mounjaro


Supplies of diabetes and chronic weight management medication, Mounjaro, are set to be limited over the coming months  Pharmaceutical company, Eli Lilly, is forecasting that supplies of Mounjaro (tirzepatide) will be limited into the New Year.   The company told the Therapeutic Goods Administration (TGA) that availability of 2.5 mg, 5 mg, 7.5 mg, 10

This content is restricted to registered users only. If you have already registered on the AJP website please login below, Or you can Register for free.

Forgot Password?Why do I need to login & stay in?

Previous CWH eyes ‘significant growth runway’ in Australia
Next Business as usual: extended OCP supply